Everest Medicines Ltd. is a biopharmaceutical company, which engages in the discovering, developing, manufacturing, and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asian markets. The firm has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The firm conducts its business in the domestic and overseas markets.